Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment

@article{Kearney2006PharmacokineticsAD,
  title={Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment},
  author={Brian P. Kearney and Kitty Yale and Jaymin Chandrakant Shah and Lijie Zhong and John F. Flaherty},
  journal={Clinical Pharmacokinetics},
  year={2006},
  volume={45},
  pages={1115-1124}
}
AbstractBackground: Tenofovir disoproxil fumarate is the prodrug of the acyclic nucleotide reverse transcriptase inhibitor tenofovir that is indicated for use in the treatment of HIV. Tenofovir is eliminated as unchanged drug in the urine, with a significant component of active tubular secretion. The aim of this study was to evaluate the pharmacokinetics of tenofovir in subjects with renal or hepatic impairment, both of which are common in HIV-infected individuals. Patients and methods: HIV… 
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
TLDR
The pharmacokinetics of TAF and TFV in HIV-uninfected subjects with severe renal impairment and matched healthy controls were evaluated and TAF exposures were higher than those for the controls but lower than the exposures in nonrenally impaired subjects on TDF-based regimens.
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
TLDR
TDF 150 mg every 24 hours provides comparable systemic exposure to the standard dose of 300 mg every 48 hours in patients with moderate renal impairment, and Concomitant LPV/r use markedly increased TFV plasma concentrations, and AUC0-48 h was 67% higher with the standard doses, whereas no differences in intracellular TFV diphosphate concentrations were observed.
The Frequency of Adjusted Renal Dosing of Tenofovir DF and Its Effects on Patient Outcomes
TLDR
HIV providers often failed to dose-adjust TDF in patients with creatinine clearance <50 mL/min, but dose-adjusted patients appeared to stay on their TDF-based regimens longer and have greater gains in CD4 cells.
Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B
TLDR
Hepatitis improved remarkably without any adverse drug reactions in the present case, and tenofovirdisoproxil fumarate (TDF) may be considered for chronic hepatitis B patients receiving hemodialysis.
Review: Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B
TLDR
Several recommendations that may help the clinician to prevent the development of adverse events associated with tenofovir disoproxil fumarate (TDF) treatment are outlined, along with a suggested surveillance protocol for the timely and proper identification of possible renal and bone toxicity.
Renal Concerns in the Treatment of Chronic Hepatitis B with Tenofovir
TLDR
Screening of risk factors for kidney disease before starting therapy and careful monitoring of serum creatinine, glomerular filtration rate, serum phosphate and urine analysis during treatment are advocated in patients treated with Tenofovir, in order to adjust the dose or stop treatment if needed.
Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment
TLDR
Evitegravir and COBI do not require dose adjustment in moderate or mild liver impairment, as no clinically relevant PK changes were observed for EVG or COBI in this special population of subjects with severe hepatic impairment.
Influence of Renal Function on the Single‐Dose Pharmacokinetics of Besifovir, a Novel Antiviral Agent for theTreatment of Hepatitis B Virus Infection
TLDR
The increase in plasma exposure and decrease in renal clearance suggest the need to adjust dosage regimens in patients with moderate to severe renal impairment.
Plasma Pharmacokinetics and Urinary Excretion of Tenofovir Following Cessation in Adults with Controlled Levels of Adherence to Tenofovir Disoproxil Fumarate.
TLDR
TFV measurement in plasma or urine is more indicative of last drug ingestion rather than differentiating recent adherence patterns, and relative differences in plasma concentrations and cumulative urine extraction of TFV were minor following cessation.
Population Pharmacokinetics of Tenofovir in AIDS Patients
TLDR
In a few patients, clearance (and AUC) could vary by a factor of 2 between occasions, and for a given patient, the dose should not be adapted unless the variation of concentration between 2 occasions is large, or the 24‐hour trough concentration at steady state is lower than 12 μg/L.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 13 REFERENCES
Systemic and Renal Pharmacokinetics of Adefovir and Tenofovir Upon Coadministration
TLDR
It is demonstrated that coadministration of tenofovir disoproxil fumarate and adefovir dipivoxil does not result in substantial changes to their individual pharmacokinetic profiles.
Tenofovir Disoproxil Fumarate
TLDR
Tenofovir disoproxil fumarate is an oral prodrug of ten ofovir, a nucleotide (nucleoside monophosphate) analogue with activity against retroviruses, including HIV-1, HIV-2 and hepadnaviruses, which supports a flexible once-daily administration schedule.
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
Results from 2 placebo-controlled intensification trials of tenofovir disoproxil fumarate (DF) in treatment-experienced human immunodeficiency type 1 (HIV-1)-infected patients (n=332) were integrated
Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults
TLDR
Reductions in plasma HIV-1 RNA were dose related at tenofovir DF doses of 75 to 300 mg, but there was no increase in virus suppression between the 300- and 600-mg dose cohorts, despite dose-proportional increases in drug exposure.
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
TLDR
Through 144 weeks, the combination of tenofovir DF, lamivudine, and efavirenz was highly effective and comparable with stavudine for antiretroviral-naive patients and appeared to be associated with better lipid profiles and less lipodystrophy.
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
TLDR
The combination of tenofovir DF and emtricitabineplus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efvirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs.
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
TLDR
The data indicate that use of ritonavir may increase risk of severe hepatotoxicity, and does not support withholding protease inhibitor therapy from persons coinfected with hepatitis B or C virus.
Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection.
TLDR
HIV-1–associated nephropathy is characterized morphologically by focal segmental glomerulosclerosis, tubular microcysts, interstitial fibrosis, and inflammation, and increasing evidence suggests it is due to HIV-1 infection.
Renal pathology of human immunodeficiency virus infection.
TLDR
The spectrum of tubulointerstitial lesions includes acute tubular necrosis, interstitial nephritis, diffuse infiltrative lymphocytosis syndrome, renal infection, and neoplasms including lymphoma and Kaposi's sarcoma.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
TLDR
The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
...
1
2
...